Abstract: The present disclosure relates generally to methods of treating hematopoietic cell malignancy in a subject by administering to the subject a Hedgehog (Hh) pathway antagonist, such as a Smoothen (Smo) antagonist alone or in combination with an ABL-kinase antagonist. Specifically, the disclosure relates to a method of treating hematopoietic cell malignancy in a subject by administering the Hh pathway antagonist, such as the Smo antagonist cyclopamine, in combination with the ABL-kinase antagonist imatinib.
Type:
Application
Filed:
September 11, 2009
Publication date:
April 1, 2010
Applicants:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, DUKE UNIVERSITY
Abstract: The invention relates to a method for treating and/or preventing autoimmune and/or inflammatory diseases, including the graft-versus-host disease, comprising administering to a patient in need thereof, a therapeutically effective amount of an arsenic compound or a pharmaceutically acceptable salt thereof.
Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to the subject a combination of sodium meta arsenite and/or arsenic trioxide and a cytotoxic anticancer agent, such as cisplatin, adriamycin, and taxane, such as larotaxel, orataxel, tesetaxel, docetaxel or paclitaxel. The arsenic compound(s) and cytotoxic anti-cancer agent may be administered together in a composition or separately as a combination therapy.
Type:
Application
Filed:
March 23, 2009
Publication date:
October 1, 2009
Inventors:
Angelika Burger, Hans Hendriks, Bernardus Rademaker
Abstract: The present disclosure relates to a kind of sodium alginate microsphere vascular embolus that contains water-soluble drug and preparation and application thereof. The embolus preparation falls into dry microsphere type and wet one that are made of degradable materials. The drug carrier can be sodium alginate, human serum albumin, chitosan or sodium hyalurate, solidifying and forming microsphere together with calcium ion solution under presence of static charge. The microsphere can have a diameter in the range of 20-1000 ?m and can be divided into a wide variety of sizes in case of need. The present disclosure adopts raw materials that are good at mechanical strength, bio-compatibility, bio-degradability and stability.
Type:
Application
Filed:
December 19, 2007
Publication date:
June 25, 2009
Applicant:
Beijing Shengyiyao Science & Technology Development Co., Ltd.
Inventors:
Li Xiaoping, Li Xinjian, Cui Heng, Wei Lihui, Feng Jie, Lang Jinghe, Xiang Yang, Lei Chengzhi, Hong Hong
Abstract: Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in hematopoietic malignancy cells, and determined to be associated with growth and proliferation of the malignancy cells. Accordingly, methods are provided for treating a hematopoietic cell malignancy associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a hematopoietic cell malignancy to treatment with an Hh pathway antagonist.
Type:
Application
Filed:
October 10, 2008
Publication date:
May 21, 2009
Applicants:
The Johns Hopkins University, The Board of Trustees of the Leland Stanford Junior University
Abstract: To provide a kit for cancer treatment and a pharmaceutical composition for cancer treatment that can inhibit the growth of tumors and cancers in mammals more than ever. The kit for cancer treatment includes a combination of two different drugs in a kit formulation. The first drug contains a synthetic retinoid or a pharmaceutically acceptable organic or inorganic acid addition salt thereof, and the second drug contains a chemotherapeutic agent for cancer treatment. A synthetic retinoid that can be suitably used is a benzoic acid derivative represented by the following formula (I): or a pharmaceutically acceptable organic or inorganic acid addition salt thereof.
Abstract: The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also provides methods for making the oral arsenic trioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.
Abstract: A method for using sodium meta-arsenite (AsO2?) to suppress growing of human cancer cells is provided to find a method of curing human cancers. Effects of sodium-meta arsenite (AsO2?) on various human cancer cells are investigated via in vitro cytotoxic activity and in vivo anticancer activity against nude mice. For in vitro cytotoxic activity, six (6) kinds of human cancer with nine (9) cancer cell lines, eight (8) kinds of human cancers with twelve (12) cancer cell lines and ten (10) kinds of human cancers with forty one (41) cancer cell lines are tested. For in vivo anticancer activity, two (2) kinds of cancers of human renal cancer RXF 944LX and leukemia cells are tested utilizing nude mice. Maximum tolerated dose assessment of sodium meta-arsenite (AsO2?) after daily oral gavages for 14 days were investigated for mouse, rat and pig. Subacute toxicity study of sodium meta-arsenite (AsO2?) was induced after daily oral gavages for 14 days in the mouse followed by a 28-day recovery period.
Abstract: The present invention provides targeted protein cages for the specific delivery of a variety of agents to cells and tissues and methods of use. The targeted protein cages have exterior targeting moieties and therapeutic or imaging agents which are encapsulated within the protein cages or are located on the exterior surfaces of the protein cages.
Abstract: Use of Fructus schisandrae in preparation of medicaments for preventing and reducing toxicity and side effects of antineoplastic agents. The toxicity and side effects of antineoplastic agents are cardiovascular toxicity, hepatotoxicity, nephrotoxicity, suppression of bone marrow, immunosuppression, or alopecia etc induced by antineoplastic agents. Fructus schisandrae and extracts thereof, especially ethanol extracts, schisandrin B, are effective in reducing antineoplastic agent's toxicity and side effects.
Abstract: It is demonstrated in the present invention that G-quadruplex ligands can be used to both shorten telomeres and inhibit telomerase by causing telomere uncapping. The invention relates to compositions and methods of treating cancer stem cells comprising the administration of G-quadruplex ligands, such as 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4), which can effectively inhibit or reduce the growth of cancer stem cells. The invention also relates to a synergistic effect in inhibiting or reducing the growth cancer stem cells when a G-quadruplex ligand is combined with a mitotic spindle poison, such as paclitaxel, or other agents used in the treatment of cancer and disease. The invention also relates to RHPS4 inducing non-cancerous cell and non-cancerous stem cell proliferation.
Abstract: The present invention relates to the use of arsenic compounds such as sodium meta arsenite (NaAsO2), arsenic trioxide (As2O3), and arsenic hexoxide (As4O6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in the treatment of pain, inflammation and immunological and autoimmune diseases and disorders.
Abstract: The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering a composition containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule. The composition can also contain one or more pharmaceutically acceptable carriers and/or excipients.
Abstract: The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering effective amount of arsenic trioxide to an affected patient.
Abstract: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.
Abstract: A process for preparing As4O6 comprises successively heating and cooling a mixture of natural Sinsuk and 40% alcohol in a ratio of about 1: about 1 for about 1 to about 2 hour(s) resulting in a product, successively washing the product with distilled water thereby forming washed precipitates, maintaining the washed precipitates at about ?40° C. for 24 hours, defrosting, filtering, and drying the precipitates, and successively heating and cooling the precipitates to obtain the final As4O6 product.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Grant
Filed:
January 16, 2004
Date of Patent:
January 3, 2006
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Grant
Filed:
January 16, 2004
Date of Patent:
April 26, 2005
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Grant
Filed:
January 16, 2004
Date of Patent:
March 1, 2005
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: A storage-stable biocidal aerated gel composition comprises from 30 to 97% by weight of water, from 0.2 to 5% by weight of a gelling agent selected from xanthan gum, sodium alginate and neutralised carboxyvinyl polymer from 2 to 5% by weight of a fine particulate, hydrophobic silicone-treated silica having a surface area of from 80 to 300 m2/g and from 0.004 to 20% by weight of a biocide which said composition is in the form of fine particles of an aqueous gel containing the water, gelling agent and the biocide, the surfaces of which fine particles are coated with a coating of the finely particulate hydrophobic silica. The biocidal aerated gel composition can be used to control pests using one or more appropriate biocides in the composition.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Grant
Filed:
January 16, 2004
Date of Patent:
February 15, 2005
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, AS2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i).
Type:
Application
Filed:
March 3, 2004
Publication date:
October 28, 2004
Applicants:
TTY BIOPHARM COMPANY, LIMITED, INSTITUTE OF NUCLEAR ENERGY RESEARCH ROCAEC
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
August 5, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Grant
Filed:
November 10, 1998
Date of Patent:
August 3, 2004
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
January 16, 2004
Publication date:
July 29, 2004
Applicant:
Memorial Sloan-Kettering Cancer Center
Inventors:
Raymond P. Warrell, Pier Paolo Pandolfi, Janice L. Gabrilove
Abstract: The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also provides methods for making the oral arsenic trioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.